2023

UBIP received the official PMDA factory inspection report, passed the GMP inspection by the Japanese PMDA.

UBIP's Single-Chain Immunoglobulin Fusion Proteins Platform has received approval from the United States Patent and Trademark Office. This cutting-edge technology is being utilized in our products - UB-551 and UB-853. The platform has secured patents in markets including China, Japan, Taiwan, India, Australia, Malaysia, and Hong Kong, while awaiting review for patents in Korea and Singapore.

Announcement for Submitting the three-in-one combination tablet (NDF01) for the treatment of HIV infection to TFDA for Registration of Medicinal Products.

UBI Pharma Inc. has received two prestigious awards at the 20th National Brand Yushan Awards：the Best Product Category Award for its HIV Combination Tablet (NDF01) and the Outstanding Corporate Leader Award for its Chairman and CEO.

UBI Pharma Inc. has signed an exclusive licensing and sales agreement with OU RUI Biotechnology Co., Ltd. for the investment in and distribution rights of UB-851 biosimilar drug for the treatment of renal anemia in eleven Muslim countries.

UBI Pharma Inc. Hsinchu plant passed the routine cGMP inspection of the US FDA and received the official factory inspection report (EIR, Establishment Inspection Report).

UBI Pharma Inc., the only injectable drug manufacturer in Taiwan passes the SMDC inspection in Ukraine.

Announcement Voriconazole for Injection, 200mg/vial (Single-Dose Vial), a sterile lyophilized powder injection ANDA has been approved by US FDA.

Announcement Levetiracetam, an epilepsy drug, has been approved by the Malaysian government.